Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

Merck (NYSE:MRK) announced Saturday that its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen reduced the risk of death by 20% as a first-line option for certain patients ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...